Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe
Posted by
www.biotecnika.org
Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will
commercialise NaMuscla for the symptomatic treatment of myotonia in
adults with non-dystrophic myotonic (NDM) disorders in certain
European Union (EU) territories, Lupin said in a statement.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-inks-distribution-pact-with-3-firms-to-commercialise-namuscla-in-europe/articleshow/76171829.cms
Subscribe to:
Post Comments (Atom)
Post a Comment